Molecular-Data Storage Board Examiner — Archival Computing

The mandate

The board revisits whether molecular storage can move from impressive density demonstrations to a trustworthy preservation service whose data may be requested decades later. Published capacity and media-life claims rarely include synthesis defects, physical sampling, copy scarcity, read latency, codec continuity, custody or future sequencer dependence. Prospective archive partners need a recoverability proposition, not a capsule of theoretically durable molecules.

The examiner will reserve two days monthly for committee preparation, evidence review and archive-partner challenge, plus four Helsinki sessions. A written view on a material retrieval failure or longevity claim is due within two Finnish business days. Laboratory validation, technical diligence, procurement or partner negotiation requires a separate scope and authorisation.

The fixed appointment runs nine months from March 2027. In month seven, management must defend an unseen partial-sample-loss and future-reader scenario. One three-month renewal may be approved by the full board for a named archive contract or funding gate; unused days expire and cannot be converted into laboratory direction or continuing product delivery.

The examiner has no line authority, executive authority, scientific-signing role, archive-disposition power, procurement mandate, investment vote or product approval. Management owns experiments and claims; customers retain preservation decisions. Advice cannot be marketed as proof of media lifetime, guaranteed future readability, archival certification or acceptance of any regulated retention obligation.

Interests involving molecular-storage ventures, synthesis or sequencing suppliers, archives, codec projects, investors or competing long-duration media must be disclosed as conflicts. One unrelated storage board role may continue with chair approval. Equity in an evaluated supplier or compensation contingent on a customer contract, financing or benchmark outcome is disqualifying.

Why the board wants this voice

Molecular scientists understand chemistry and coding teams understand redundancy, but the board lacks someone who has carried an archival medium through custody, generational migration and rare retrieval failure. That voice can expose unpriced future dependencies and sampling loss without selling sequencing capacity or claiming scientific authority over accelerated-ageing evidence.

What you will own

• Press directors to trace source object, encoding, oligo design, synthesis batch, physical pool, custody, sample, read, decode and verification.
• Test density and durability claims after redundancy, indexing, failed molecules, aliquot loss, quality controls and retained recovery material.
• Challenge retrieval economics for rare access, partial reads, urgent requests, future sequencers and long-idle laboratory capability.
• Frame scenarios involving contaminated pool, lost aliquot, obsolete codec, supplier exit, reader drift and incomplete chain of custody.
• Probe evidence behind accelerated ageing, environmental tolerance, copy creation, geographic separation and claimed energy advantage.
• Examine customer obligations for integrity checks, migration triggers, legal holds, deletion evidence and intelligible failure notification.
• Coach directors to distinguish molecular persistence, recoverable information, operational retrieval and contractual preservation assurance.

Candidate qualifications

• Held senior molecular-storage, archival systems, coding or long-duration preservation authority spanning laboratory and service operations.
• Reconciled source data, codec versions, synthesis batches, physical samples, sequencing reads and decoded output after defects or loss.
• Challenged storage-density and lifetime claims using full redundancy, custody, retrieval, migration and future-reader assumptions.
• Governed rare-access archives where operational readiness and provenance mattered more than frequent performance benchmarks.
• Presented stop, scale and partner choices to boards, archival institutions and investors under deep technical uncertainty.
• Managed conflicts across molecular ventures, synthesis and sequencing vendors, archives and competing media while protecting unpublished evidence.

Non-negotiables

• Can attend all four Helsinki sessions and respond within two business days to a declared retrieval-evidence event.
• Will disclose storage, synthesis, sequencing, archive, codec and investor interests before receiving benchmark evidence.
• Accepts literal absence of line, executive, scientific, archive, procurement, investment and product authority.
• Must evidence an archival recovery or media-transition failure; general biotechnology or cloud-storage strategy is insufficient.

1. 49 words maximum. Describe a molecular or archival density claim that weakened after full recoverability costs were included.
2. 49 words maximum. Which current storage, synthesis, sequencing, archive or investor interests require board disclosure?
3. 49 words maximum. How would you test future readability without pretending accelerated ageing proves decades of service?